278 results
8-K
EX-99.1
OGEN
Oragenics Inc
7 May 24
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
8:14am
of its product candidates; the regulatory application process, research and development stages, and future clinical data and analysis relating to its
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
will become available and our research and development programs;
Our ability to timely and successfully achieve the anticipated benefits of acquiring … ability to continue research and development for existing product candidates on previously-projected timelines or in accord with ordinary practices
8-K
EX-99.1
OGEN
Oragenics Inc
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
of its product candidates; the regulatory application process, research and development stages, and future clinical data and analysis relating to its
424B5
OGEN
Oragenics Inc
27 Feb 24
Prospectus supplement for primary offering
5:04pm
work, the period during which the results of the trials will become available and our research and development programs;
Our ability to timely … approve our product candidates prior to substantial research and development and could restrict or delay the future commercialization of certain of our
8-K
EX-99.1
9za niq25ip
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
EX-99.1
s4qgv
5 Feb 24
Other Events
8:00am
8-K
b06x7b
16 Jan 24
Other Events
9:10am
424B5
gk8y m1cg
16 Jan 24
Prospectus supplement for primary offering
9:04am
8-K
EX-99.1
8utg45
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
EX-10.1
497bw62wgdhawtsz
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
EX-99.1
hnam2y 026zd0pih8bl
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
DEFA14A
lb4pto5lu
2 Nov 23
Additional proxy soliciting materials
7:00am
8-K
EX-2.1
67oyv3xrlkfx3q7d3n
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
p06o7ygoznuizzh
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
EX-99.1
ccxo6pvgi7g6v7zm9xx
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
4ik6ju aa544c22hst
29 Sep 23
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
4:00pm